Aton Ra Partners Bio N Tech Se Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Bio N Tech Se stock. As of the latest transaction made, Aton Ra Partners holds 4,175 shares of BNTX stock, worth $476,492. This represents 0.88% of its overall portfolio holdings.

Number of Shares

4,175

Previous 4,707 11.3%

Holding current value

$476,492

Previous $511,000 13.89%

% of portfolio

0.88%

Previous 1.07%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$90.91 - $112.75 $48,364 - $59,983	-532 Reduced 11.3%	4,175 $440,000
Q3 2023 Oct 25, 2023	SELL	$98.5 - $125.08 $99,189 - $125,955	-1,007 Reduced 17.62%	4,707 $511,000
Q2 2023 Jul 18, 2023	SELL	$102.58 - $129.66 $17,951 - $22,690	-175 Reduced 2.97%	5,714 $616,000
Q1 2023 May 05, 2023	SELL	$122.57 - $153.67 $62,142 - $77,910	-507 Reduced 7.93%	5,889 $733,000
Q4 2022 Feb 02, 2023	SELL	$118.43 - $186.05 $269,546 - $423,449	-2,276 Reduced 26.25%	6,396 $960,000
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $5,616 - $8,056	-44 Reduced 0.5%	8,672 $1.17 Million
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $547,723 - $827,650	-4,444 Reduced 33.77%	8,716 $1.3 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $21,967 - $40,341	-174 Reduced 1.3%	13,160 $2.25 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $182,194 - $304,879	-841 Reduced 5.93%	13,334 $3.44 Million
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $735,787 - $1.6 Million	-3,573 Reduced 20.13%	14,175 $3.87 Million
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $397,413 - $846,905	3,507 Added 24.63%	17,748 $3.97 Million
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $196,407 - $273,774	2,291 Added 19.17%	14,241 $1.56 Million
Q4 2020 Feb 19, 2021	BUY	$72.71 - $129.54 $868,884 - $1.55 Million	11,950 New	11,950 $974,000

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account